A Phase I Study of Aerosolized Administration of tgAAVCF to Cystic Fibrosis Subjects with Mild Lung Disease

Abstract

Cystic fibrosis (CF) is one of the most common autosomal recessive disorders in North America, leading to significant morbidity and early mortality. The defect in the cystic fibrosis transmembrane conductance regulator protein (CFTR) function can be corrected in vitro by gene replacement with a wild-type gene. A Phase I, single administration, dose escalation trial was designed and executed to assess safety and delivery of tgAAVCF, an adeno-associated virus (AAV) vector encoding the human CFTR cDNA, by nebulization to the lungs of CF subjects. Four cohorts of three subjects each were administered increasing doses of the study agent, beginning with 10(10) DNase-resistant particles (DRP) and escalating in log increments up to 10(13) DRP. Sequential bronchoscopies were performed to gather analytical samples throughout the study. All 12 subjects completed the study. There were a total of 242 adverse events (AEs), six of which were defined as serious and three of which were defined as possibly being related to the study drug. A clear dose-response relationship was observed in vector gene transfer. A maximum of 0.6 and 0.1 vector copies per brushed cell were observed 14 days and 30 days, respectively, following nebulization of 10(13) DRP tgAAVCF, and this declined to nearly undetectable levels by day 90. Vector gene transfer was evenly distributed throughout the fourth airway generation following single-dose administration. RNA-specific PCR did not detect vector-derived mRNA. This Phase I trial shows that aerosolized tgAAVCF is safe and widely delivered to the proximal airways of CF subjects by nebulization.

Cross‐talk of alpha tocopherol‐associated protein and JNK controls the oxidative stress‐induced apoptosis in prostate cancer cells

“…AAV is an attractive candidate for gene therapy. [32][33][34][35] There are many serotypes of AAV. Among them, AAV2 is the most popular one for scientific research.…”

Strategies for improving the transduction efficiency of single-stranded adeno-associated virus vectors in vitro and in vivo

“…It is, nonetheless, tempting to speculate that at the very least, the therapeutic vector dosage could be reduced by a log to overcome problems associated with vector load and immune response seen in clinical trials. 35 Furthermore, given that AAV2 remains the sole serotype vector currently in use in human gene therapy, 20,21,[36][37][38][39][40] coupled with the fact that it is also the best characterized in terms of vector toxicology, it is conceivable that this strategy could be employed to augment transgene expression scAAV2-TC-PTP and scAAV2-PP5 as helper viruses for ssAAV2 vectors GR Jayandharan et al from single-stranded vectors containing large genes such as coagulation factor VIII in the liver in clinical trials in patients with hemophilia A. In our current studies, the TC-PTP and the PP5 genes were under the control of the RSV promoter.…”

Gene Therapy Progress and Prospects: Cystic fibrosis

“…However, vector-specific mRNA could not be detected and therefore evidence for gene transfer was not provided. 5 In summary, these new studies consolidate the view that proof-of-principle of gene transfer can be demonstrated in some, but not all studies, but that gene transfer efficacy is currently insufficient to warrant phase II/III trials. Thus, significant improvements in all aspects of gene transfer need to be made.…”